Lead Product(s) : Anamorelin HCl
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Oberland Capital Management
Deal Size : Undisclosed
Deal Type : Financing
Helsinn Closes Financing Agreement with Oberland Capital
Details : Adlumiz (anamorelin) is a selective, novel, orally active ghrelin receptor agonist. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite and metabolism.
Product Name : Adlumiz
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 01, 2023
Lead Product(s) : Anamorelin HCl
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Oberland Capital Management
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Anamorelin HCl
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Marketing approval of Adlumiz® (generic name: anamorelin hydrochloride) Tablet 50mg (“Adlumiz”) is mainly based on the results from the ONO-7643-04 and ONO-7643-05 studies conducted in Japan in patients with cancer cachexia.
Product Name : Adlumiz
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2021
Lead Product(s) : Anamorelin HCl
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
